Fresh Paint · The Frame
Would You Go to China to Cure Your Dad's Cancer?
The molecule isn't the prize. Access is. When the cure turns cheap to make, value walks out the door with the patient — and into whoever holds the relationship.
In Chicago last week, at the annual meeting of the American Society of Clinical Oncology, the most prestigious cancer conference in the world, one of five coveted plenary slots went to a drug developed entirely in China — the first time in ASCO's six-decade history a China-only asset had earned the primetime stage.
The trial belonged to Akeso, a publicly traded biopharmaceutical company based in Zhongshan, on the western side of the Pearl River Delta in southern China. Akeso's lung-cancer drug cut the risk of death by a third against the standard immunotherapy regimen, and an earlier trial of the same molecule had already bettered Merck's best-in-class Keytruda.
Marjorie Green, the head of global oncology development at Merck, sounded almost admiring in an interview: "We see a lot of sophistication and skill in Chinese companies." The National Security Commission on Emerging Biotechnology, the bipartisan panel Congress created to track the race, was blunter: in February it warned that "the United States is losing." And Albert Bourla, the CEO of Pfizer, had conceded the harder competitive reality on an earnings call last year: "You won't slow them down."
The Fear runs through the American drug market now.
China publishes more high-impact biotech research than the United States and Europe combined, runs more clinical trials, and has passed the West in whole fields — synthetic biology, genomic sequencing, the antibody-drug conjugates big pharma licenses as fast as Chinese firms put them out. By 2025 China produced roughly a third of the world's innovative-drug pipeline, pulling within a few points of the United States after trailing by thirteen points two years earlier. Chinese companies signed about half of the world's drug-licensing deals by dollar value — a record near $135 billion, nearly triple the year before — while the U.S. share fell toward a quarter. The market value of its listed biotech firms has reached about $1.5 trillion, second only to the United States.
By every measure of making a drug, China has arrived.
The story everyone tells is the obvious one, now maximally predictable. China is catching up. China is passing us. China will own the next generation of cures.
It is a story the United States has told itself before, about one industry after another. Steel told it first. Then consumer electronics, then solar panels, then cars and the batteries that move them — each time the same three beats: catching up, passing us, owning what comes next. Pharma is only the newest tile in a row that has been falling for forty years. The domino theory used to be about nations going red, the Cold War conviction that one country falling to communism would tip the next, and the next. Now it is how America narrates its own industries falling to China, the groove worn so deep the country recites it in its sleep.
That is the first thing wrong with it.
A story this familiar has no power left to move anyone. There is no 'narrative surprise' in it. It gets recited, agreed with, and acted on everywhere, but strategically nowhere — not because The Fear is wrong, but because the story has gone inert.
Inert or not, the story still sets the response, and the response is already underway, running two directions at once. One is to invent faster: more than $17 billion has gone into AI drug discovery since 2019, on the wager that software will let America out-discover China. The other is to wall China off: days ago John Moolenaar, the Republican who chairs the House's select committee on China, joined a Michigan Democrat to introduce the Biotech Investment National Security Act, putting American investment in Chinese biotech under national-security review. Build faster, or fence the rival out — every dollar and every clause aimed at the same target.
The second thing wrong is the main character.
The story fixates on the hero who invents the cure, because technical invention — frontier innovation — used to be the prize. For a century it was. That industrial-age commercial model is disintegrating. When the molecule turns cheap to find, the scarce thing is no longer the discovery but the spread of it — the reach, the access, the getting of a cure into a body, at scale and speed.
Diffusion beats invention now. The FDA still clears a molecule faster than China's regulator does, and it does not matter, because China has spent a decade compressing the wait between approval and the patient: for rare-disease drugs, the delay behind the United States has fallen from more than thirty years to about one. Diffusion, engineered. A country still treating discovery as the main event is defending ground that has already shifted beneath it.
The fence fails the same way. It guards the lab — the bench where the molecule gets made — but the bench was never where the value settled. You can wall American capital out of every Chinese lab and still lose, because what you are chasing was never on the bench. It walked out the door with the patient.
The question that should keep an American pharma board awake is not whether China can out-build the cure. It is what happens when China stops trying to sell the cure and starts giving it away.
A Crazy Hypothetical
AI is starting to do to the cure what it did to code.
Last week Alnylam, a pioneer of RNA medicine, committed up to $2 billion to set an AI model loose on its twenty years of data, a bet that software can find a drug faster than a scientist can. The same day, Chai Discovery, a two-year-old startup backed by OpenAI whose AI designs antibodies that bind a hundred times tighter than its models could a year ago, signed both Pfizer and Eli Lilly and went out to raise money at a $3.4 billion valuation. The cost of finding a molecule that works is collapsing the way the cost of writing software collapsed, not to zero, but to the point where the discovery stops being the scarce thing. The artifact commoditizes.
None of this arrives next year. The first medicines designed this way reach patients in the 2030s, not now, and a skeptic is right to say so. But direction is the whole argument: the molecule is sliding from scarce to cheap, and the asset that replaces it — the relationship around the cure — takes its own decade to build. Both clocks started together. Whoever waits for proof will be building against someone who began a decade early.
A drug that cures a cancer, or holds it in check, stops being a miracle locked behind a twenty-year patent and a million-dollar price. It becomes a known recipe, made wherever production is cheapest and the regulator is fastest. Discovery is no longer the hard part. The American way of managing healthcare is.
The West is still fixated on making the drug-industrial complex more efficient, more productive, more transparent; the moat to cross, though, is the administrative-industrial complex, the hand built to be invisible — the prior authorization and utilization management that decide whether your father can even start a better drug for his lung cancer, the rebate haggled in private between maker and middleman, the copay that turns a working drug into what oncology now calls financial toxicity.
The shareholder reads that as a margin problem. You read it differently.
Your father's lung cancer is caught early, years before it would announce itself, because the biomarker screen that sees it coming is nearly here. It will not be cured in an afternoon. It will be managed — held in check, watched, adjusted — across the years as lung cancer becomes a chronic disease, something people live with instead of die from. The molecule does that work. The open question is who builds the rest of it: the frontier-management part, the continuous health engagement wrapped around the molecule and folded into one standing relationship.
A clinic in Shanghai can treat your father. A clinic in Boston can treat your father. The molecule is the same molecule. One of them costs a fraction of the other and arrives wrapped in a program that flew you and your father over to China, booked the follow-ups, and assigned a doctor who checks in by app for the rest of his life.
And the program is doing more than treating him. It is learning from him. Every check-in, every scan, every reading off his body becomes biological data, the data becomes evidence, and the evidence rewrites the standard of care for the next patient. The molecule is fixed; anyone can make it. The medicine practiced around it grows sharper and more personal with every life it manages, and that — the standard of care, compounding, owned — belongs to whoever holds the relationship. Boston dispenses the drug. Shanghai runs the loop.
Everything in you resists this. You do not trust the regulator, you do not trust the platform, and you do not like that the price of the cheaper cure is your father's body turned into data on a server in Shanghai. Those are the shareholder's objections. The son has one fact to set against them: his father gets well. The privacy you are guarding is a luxury of a man whose father is not dying.
Call it the narrative frame: the strategy story that holds the molecule, set above it, where the value now lives. It should surprise no one that China has already built the thing the story describes, or that almost no one in American healthcare sees it as competition.
The Infrastructural Advantage
Ping An Good Doctor runs an AI family-doctor system trained on 1.44 billion consultation records, handling up to four million AI visits a day, with more than thirty-five million people enrolled in its family-doctor membership. It is not a drug company, and it does not make cures. What it has built is the layer around the cure — the care-and-service infrastructure a drug company would need and does not have: the permanent relationship with the well and the unwell alike, the engagement that begins a decade before the diagnosis and never ends. When the molecule is cheap, that relationship is the scarce asset, and Ping An already owns it at the scale of a nation.
And it has just turned the corner into real money. After its first full year of profit in 2024, net profit jumped 366 percent in 2025 — and the business that grew fastest was the one selling continuous health management to employers, up more than 40 percent year on year. The piece that sells the relationship itself is the piece the market is now paying for. And it already reaches into the West for the authority its users want. Ping An pipes second opinions from overseas top-tier physicians into the same app, delivered to the same home. Western expertise does not have to be owned to be sold; it becomes a feature the platform sources on demand and resells inside the relationship it already holds.
The American specialist is the consumable. The Chinese platform is the standing asset.
Couple that platform to a commoditized cure and link both to a visa, and you have an export the United States currently has no strategy for. Medical tourism stops being a workaround for the uninsured and becomes a national value-capture strategy. (Blue Spoon's Cardiac Borough series works this out in full.) The country that produces a flow of affordable cures, links them to access, and wraps the access in continuous health engagement does not need to win the per-unit price war at home. It captures the value up the stack, in the relationship, the way the operating system captured what the chip could not.
Fear and Loathing in the Doldrums
In February, Congress passed the largest package of pharmacy-benefit-manager reform in history. Within the week, everyone declared victory and blamed someone else.
The drugmakers' lobby called it a win for patients. The benefit managers' lobby called the reforms unnecessary and pivoted to a seven-figure ad campaign pointing at the drugmakers. The insurers ran spots telling Americans how much of every premium dollar goes to pharma. The drugmakers called the insurers' ads misinformation. The hospitals defended their drug discounts. The biotech lobby warned that any pressure on price means fewer cures.
Every one of those positions is exactly the one you would predict from someone defending an antique narrative. PhRMA defends the molecule because PhRMA is the molecule. PCMA defends the spread because PCMA is the spread. AHIP blames the manufacturer, the AHA protects the discount, BIO invokes the dying patient to protect the price. There is no narrative surprise anywhere in it, and a position with no narrative surprise cannot move anyone. Every voice in the room says the one thing it was built to say. The sound is enormous. Nothing in the room moves.
This is structural stalemate; not any one group's failure of messaging per se but what all of it adds up to. They are fighting over the distribution of margin on a scarce cure — who keeps the rebate, who sets the formulary, who eats the discount — inside the Standard Model Pharma cost-access-value frame, the only frame any of them knows.
And the whole argument is about to be made irrelevant by a fact none of the combatants has priced in. They are dividing a pie that AI is about to bake for almost nothing, in a kitchen someone else is building. When the cure commoditizes, the question of who keeps the margin on it stops mattering, because the margin goes to whoever holds the relationship — and not one of these organizations is building the relationship. They are litigating the price of a thing that is becoming cheap while ceding the thing that is becoming dear.
A Better System of Markets
A system-level problem carries a certain amount of complexity, and a response that hopes to govern it has to carry at least as much.
Reorganizing the nature of competition around the production of affordable health touches the molecule, the diagnosis, the data, the payment, the relationship, a twenty-year arc — currently every player owns one piece and defends it to the exclusion of the rest. The drugmaker cannot build the frame from the molecule, the insurer cannot build it from the premium, the benefit manager cannot build it from the rebate, the hospital cannot build it from the bed. Building it means crafting a better system of markets out of those pieces, and a system is exactly the thing a room full of single seats cannot produce. What looks like a turf war is a refusal to interoperate, and the refusal is fatal, because the country closest to building the frame is not waiting for the room to agree.
What it would look like is not exotic. An American platform that catches the cancer a decade early with the screen now arriving, manages it across the two decades it has become survivable, and owns the relationship and the compounding data the molecule throws off — built here, on American data, under American law. Every piece is already on the table. No one has put them together.
This is the work. Not a louder argument from one chair against another, and not the same chairs somehow agreeing — the room cannot agree, which is the whole problem. It is the construction, across those seats, of a new economic concept none of them can build apart: the production of affordable health as the thing a new industry ecosystem sells, the relationship as the thing it keeps. It takes someone with no single seat to defend — a new entrant, or the rare incumbent willing to walk off its own position. It is harder than another ad campaign, and it is the only move on the board that is not already obsolete.
So the real question is not whether the cure gets cheaper. It will.
It is whether America builds the frame to compete on access before anyone else does. If it doesn't, you already know your answer, because you will be standing in a clinic with a father who is going to get well, looking up at the flag over the door and finding, to your own surprise, that you do not care which one it is.
/ jgs
John G. Singer is the founder and Executive Director of Blue Spoon and the author of When Burning Man Comes to Washington: A Field Manual for Riding Chaos. Hardcore Zen is published weekly on Substack.